RxDoctor Payments Data

Manoj Khatore, MD

Cardiovascular Disease · Oxnard, CANPI 1528140639

Payments from drug & device makers

$6,057in general payments, 2019–2025

Across 225 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$841
  • AstraZeneca$799
  • Abiomed$681
  • Novartis$515
  • Actelion Pharmaceuticals US, Inc.$490
  • Bayer$344
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$4718%
  • Food & beverage$5,30988%
  • Education$2775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,057 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,543,675
Medicare patients
904
Services billed
19,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$313,237
XareltoRivaroxaban215$255,004
JardianceEmpagliflozin201$211,147
FarxigaDapagliflozin Propanediol129$115,599
EntrestoSacubitril/Valsartan78$92,294
VerquvoVericiguat45$65,138
OzempicSemaglutide47$60,425
InpefaSotagliflozin45$46,465
BrilintaTicagrelor34$27,448
Repatha SyringeEvolocumab23$21,957
Repatha SureclickEvolocumab25$19,589
NexlizetBempedoic Acid/Ezetimibe21$12,771
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,843
Ranolazine ErRanolazine125$9,433
Eplerenone166$8,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$181$313,237329 claims
Johnson & JohnsonXarelto$154$255,004215 claims
Boehringer IngelheimJardiance$306$211,147201 claims
AstraZenecaFarxiga, Brilinta$799$143,047163 claims
NovartisEntresto$515$92,29478 claims
MerckVerquvo$278$65,13845 claims
Novo NordiskOzempic$46$60,42547 claims
Lexicon Pharmaceuticals, Inc.Inpefa$73$46,46545 claims
Esperion Therapeutics, Inc.Nexlizet$270$12,77121 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$12$7,87312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →